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Introduction
Paliperidone is an atypical antipsychotic derived from 
9-hydroxyrisperidone. Paliperidone shows antagonistic activity on 
dopamine D2, serotonin 5HT2A, and histamine H1 receptors as 
well as the alpha1 and alpha2 adrenergic receptors1. Paliperidone 
palmitate is an injectable form of paliperidone that has long-lasting 
potency and has been developed to improve treatment compliance in 
patients who have schizophrenia. Paliperidone shows high binding 
affinity to dopamine D2 and serotonin 5HT2A receptors. It also 
shows significant binding affinity to α2a receptors. This leads to an 
increase in serotonin release, which may also induce antidepressant 
activity2. Although it seems to be paradoxical, manias that are 
associated with atypical antipsychotic drugs have been reported in 
the literature3. However, very little research has been published on 
paliperidone- and paliperidone palmitate-induced mania1,4. This 
report will discuss the case of a patient who was hospitalized with a 
diagnosis of schizophrenia and manic symptoms during paliperidone 
palmitate treatment.
Case report
A 27-year-old male was diagnosed with paranoid schizophrenia 
six years ago. His initial complaints were social and emotional 
withdrawal and referential, persecutory, and nihilistic delusions. 
Treatment with oral haloperidol 20 mg was started, but his psychotic 
symptoms did not improve so he was switched to olanzapine 15 mg/
day. His symptoms improved with the olanzapine treatment. In the 
follow-up visits, the olanzapine dosage was reduced to 10 mg/day 
because of the metabolic side effects of olanzapine, and the patient 
was in remission for two years. However, his psychotic symptoms 
began to worsen due to poor treatment compliance with regard 
to taking the olanzapine. The patient was hospitalized, and the 
olanzapine dose was increased to 30 mg/day. His psychotic symptoms 
abated with this treatment regime, and he remained in remission 
while taking the olanzapine 30 mg/day until 2018. However, his 
psychotic symptoms worsened, once again due to poor medication 
compliance, and he was involuntarily hospitalized. Because of his 
reduced compliance to oral medication, long-acting paliperidone 
palmitate treatment was planned. Treatment with oral paliperidone 
6 mg/day was started, and a paliperidone palmitate injection was 
scheduled for the 10th day of taking the oral paliperidone. Oral 
paliperidone treatment was stopped at the 15th day of the initial 
injection of paliperidone palmitate. The initial dose was set at 150 
mg for the first treatment, increasing to 100 mg for the eighth, 
and staying on a maintenance dose of 100 mg for the first month. 
Because of the continuation of his symptoms after the maintenance 
dose of 100 mg, the next paliperidone palmitate injection was set at 
150 mg, and oral paliperidone 6 mg/day was added to the treatment 
regime until the next injection. One week after he had been given 
this treatment, the patient started to experience decreased sleep 
requirements, logorrhoea, grandiosity, euphoria, and psychomotor 
agitation. His score on the Young Mania Rating Scale (YMRS) was 
30. Clonazepam 3 mg/day was added to control the manic symptoms. 
Although the patient’s mobility decreased and his sleep improved, he 
continued to experience grandiosity, and sodium valproate 500 mg 
was started and gradually increased to 1,500 mg/day. Three weeks 
after the addition of the sodium valproate (VPA: 117 mEq/lt), the 
patient’s YMRS score had decreased to 26. The paliperidone palmitate 
injections and oral paliperidone were discontinued and replaced 
by clozapine. By the third week, the patient’s manic symptoms had 
decreased with a dosage of clozapine 400 mg/per day (YMRS:16). 
The clozapine was gradually increased to 700 mg/day, and his last 
YMRS score before discharge from hospital was 6. After discharge, 
the patient was treated with clozapine 700 mg and sodium valproate 
1,500 mg/day and did not show any reoccurrence of psychotic, manic, 
or hypomanic symptoms. 
Discussion
Here we reported on the case of a patient who had a diagnosis of 
schizophrenia and developed manic symptoms after being treated 
with paliperidone palmitate. Although the patient had been taking 
antipsychotic medication for six years, no manic symptoms had 
been found during this time. The emergence of manic symptoms 
after paliperidone palmitate treatment with no other combination 
medication suggests causality: that the patient’s manic symptoms 
were due to the paliperidone palmitate treatment. There have 
been reports of cases of mania with atypical antipsychotics such as 
risperidone, aripiprazole, and quetiapine3. However, reports of mania 
cases that were induced by paliperidone are limited1,4,5. 
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Paliperidone, is a new atypical antipsychotic drug. Although 
risperidone has antimanic activity, it has also been reported to induce 
mania in some cases4. Atypical antipsychotic-induced mania has 
been reported as being associated with frontal dopamine release via 
the 5HT2A receptor blockade3. Paliperidone also has D2 and 5HT2A 
receptor blockade activity. In addition, paliperidone has significant 
α2A antagonistic activity, and this antagonism tends to increase the 
release of serotonin. This increase in serotonin is associated with the 
antidepressant activity of paliperidone2,4 and it is believed that this 
serotonergic effect might contribute to the development of manic 
symptoms. After taking a single dose of paliperidone palmitate, 
which has long-lasting potency, the plasma level gradually increases 
and reaches Tmax on the 13th day. The release of paliperidone 
palmitate into the plasma begins from the first day and continues 
for four months. Furthermore, paliperidone palmitate rapidly 
reaches therapeutic concentration in the first week following the 
administration of the two initial doses, and adding oral paliperidone 
is, therefore, not recommended due to the rapid therapeutic effect of 
paliperidone palmitate after the onset of this regimen4. Although the 
pharmacological properties and possible antidepressant efficacy of 
paliperidone may have caused symptoms of mania in our case, it is 
not possible to provide a full explanation of the relationship between 
paliperidone palmitate treatment and mania from our case report alone. 
Nevertheless, this case suggests that patients with schizophrenia 
should be carefully monitored during the transition to paliperidone 
palmitate with long-lasting potency, to watch for the development 
of symptoms such as mania. Further studies are needed to clarify the 
mechanisms of this clinical condition. 
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